The authors have requested that this preprint be withdrawn due to author disagreement.
Article
WITHDRAWN: Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination Deficiency, without germline BRCA1/2 mutation
https://doi.org/10.21203/rs.3.rs-78109/v2
This work is licensed under a CC BY 4.0 License
published 30 Nov, 2021
posted
You are reading this latest preprint version
The full text of this preprint has been withdrawn by the authors while they make corrections to the work. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.
Editorial notes are used to provide important context regarding the topic of a preprint or to alert readers to potential issues concerning that preprint or a downstream publication associated with it. For more information on editorial notes, see our Editorial Policies.
The authors have requested that this preprint be withdrawn due to author disagreement.
The authors have withdrawn this preprint from Research Square.
Yes there is potential Competing Interest.
Fabrice André received research fundings and served as speaker / advisor (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly.
Anne PATSOURIS received consulting fees (e.g. advisory boards) and served as a speaker (both compensed to the hospital) for Pfizer, Lilly, received travel fees from Roche, Esai, Amgen, Pfizer.
Olivier TREDAN received research grant from Roche, MSD-Merck, BMS, personal fees from Roche, MSD-Merck, Pfizer, Lilly, Astrazeneca, Sandoz, Novartis-Sandoz, Daiichi Sankyo and travel fees from Eli-Lilly, Pfizer, Novartis, Astra Zeneca.
Monica ARNEDOS received research grant from Eli-Lilly, honoria from Pfizer, Novartis, Astra Zeneca, Seattle Genetics and Abbvie, travel fees from Roche, Astra Zeneca and Novartis
23
Anthony GONCALVES received research fundings and served as speaker / advisor, compensated to the hospital for Astra Zeneca, Pfizer, Novartis, Roche, MSD, Lilly
Cecile VICIER received research grant from BMS and travel fees from Pfizer, Astellas and Roche.
Andrea LOEHR is affiliated to Clovis and a no competing interest to disclose otherwise.
published 30 Nov, 2021
posted
You are reading this latest preprint version